NZBIO Conference 2010 - New Zealand's Premier Bio Event

Advancing a Biobased economy. 21-24 March. Auckland, New Zealand

Satellite Events

 

NZAQ BioFuels Forum

 

Wednesday 24 March 2010, 12.45-2.30pm, SKYCITY Convention Centre

The New Zealand and Queensland Biotechnology Alliance will be holding a Biofuels Forum at the NZBIO 2010 conference.  This Forum will provide opportunities for the development of Trans-Tasman collaboration in Sustainable Biofuels.

Please note: Lunch will be available for conference attendees.

This Satellite Event will be free for NZBIO 2010 Conference Attendees - click here to register

For people not attending the NZBIO 2010 Conference, you can register through the NZBIO Events Calendar here

 

Draft Programme

“The NZAQ Biotech Alliance”            
Speaker: Dr Stuart Hazell, Industrial Affiliates Co-ordinator, Australian Institute of Bioengineering and Nanotechnology (AIBN)
 
“New Zealand and Queensland Government Perspectives on Biofuels” 
Speaker from NZTE: Dr Kathryn Jones, Sector Manager, Food & Beverage/Biotechnology
Speaker from QLD Govt: tba
 
“Biofuels for Aviation”
Speaker: Brad Wheatley, Research Leader - Environment, Boeing
 
“Current capabilities in Second Generation Biofuels” 
Speakers:
·                     Dr Stuart Hazell, Industrial Affiliates Co-ordinator, AIBN;
·                     Associate Professor Ben Hankerman, Director Solar Biofuels Consortium,
                       Institute for Molecular Bioscience;
·                     Garry Henderson, KBR Engineering;
·                     Gary Brockett, CEO, Ecodiesel;
·                     Dr Trevor Stuthridge, Group Manager - Sustainable Design, Scion
 
 
Facilitated Panel Discussion: “Possibilities for trans-Tasman Collaborations”
Chair: Dr Stuart Hazell, Industrial Affiliates Co-ordinator, AIBN

 

Deal & Company Valuation Techniques Workshop - When LEO Bought Peplin - Fair Deal or a Steal? 

Presented by: Shane Storey, Healthcare & Biotechnology Analyst, Wilson HTM

 

Wednesday 24 March, 4.00-6.00pm, SKYCITY Convention Centre

 

NZBIO has been open in supporting the Government’s intent to improve the capital markets in New Zealand. The lack of a vibrant capital market and a small listed exchange has seen many of our most promising companies sold off-shore or relocated to countries with deeper capital pools. One of the key issues facing small-cap, high technology equities is the lack of research and specialised analysts.

 

As such NZBIO is very pleased to have secured Dr Shane Storey, Senior Research Analyst (Life Sciences) Wilson HTM to provide examples of the techniques used by specialised industry analysts, in the context of one of 2009’s most significant Australasian biotechnology acquisitions. This workshop is the first of its type to be run by NZBIO and offers significant value to Chief Executives, Business Development and Commercialisation Managers and Investors alike.

Bronwyn Dilley, Chief Executive, NZBIO

 

When LEO Pharma acquired Peplin Inc (ASX:PLI) for US$287M in 2009, some investors said: "Is that all?".  In this valuation workshop, Shane Storey (Wilson HTM) hosts an interactive case-study, looking at the LEO-Peplin transaction from an analyst's perspective.  The session will look at the valuation techniques used to value Peplin including discounted cash flow and real options analysis. 

To register click here

 

Draft Programme

Session I – Understanding Peplin Inc – What was on the block?

  • Company history
  • PEP005 for actinic keratosis – an introduction to Peplin’s business
  • Exercise I – Forecasting PEP005 sales in the US dermatology market

 

Session II – Discounted Cash Flow Valuation of Peplin Inc

  • Why is cash flow so important?
  • What are the important concepts of company valuation?
  • Among how many shares should the value be divided?
  • Exercise II – Building a quick DCF to value Peplin

 

 Session III – Does DCF fail biotechs?  Can option pricing help?

  • Are biotechs proper companies or just “punts”?
  • Option pricing prices “punts” – here’s how
  • Exercise III – Building a quick option pricing model to value Peplin

 

Session IV – Was the LEO-Peplin deal fair to shareholders?

  • Who got it right?  The market or the analysts?  Why.
  • What did LEO really buy?
  • Questions

 


Wednesday 24th

12:45

NZAQ BioFuels Forum

Presented by New Zealand Queensland Biotechnology Alliance

16:00

Deal & Company Valuation Techniques

When LEO Bought Peplin - Fair Deal or Steal?

 

Gold Partners

Silver Partners

Bronze Partners

International Networking Reception

Awards Dinner Partner

Conference Partners

Media Partners

NZBIO Partners